Mass. Ethics Code Compromises Drug Development, Industry Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Reporting provisions in state law signed Aug. 10 expose clinical researchers, drug company programs, state and national organizations say.
You may also be interested in...
Revised Sunshine Act Pre-empts State Reporting Duplications, Not Differences
Senate Finance Committee Investigative Counsel Christopher Armstrong said the goal of pre-emption provisions in the latest version of the Physician Payment Sunshine Act is to create neither a floor nor ceiling for state reporting requirements, but merely to prevent duplicate reporting on state and federal levels
Revised Sunshine Act Pre-empts State Reporting Duplications, Not Differences
Senate Finance Committee Investigative Counsel Christopher Armstrong said the goal of pre-emption provisions in the latest version of the Physician Payment Sunshine Act is to create neither a floor nor ceiling for state reporting requirements, but merely to prevent duplicate reporting on state and federal levels
Small Biotechs Could Suffer Under State Bans On Selling Physician Rx Data, BIO Says
Bans on the practice, like the recently upheld New Hampshire law, could have an unintended financial consequence on small biotech companies, BIO warns.